2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Investor Profile Country Deals
T Rowe Price Group Inc Asset management firm. United States 6
The Blackstone Group LP Private equity firm United States 6
Triathlon Medical Ventures LLC United States 6
Wellington Partners United States 6
Abbott Laboratories United States 5
ABS Ventures United States 5
Advantage Capital Partners United States 5
Advent Venture Partners LLP Originating in 1981, Advent Venture Partners was one of the first US-style venture capital firms in Europe United Kingdom 5
Albion Ventures LLP Albion Ventures was established to generate long term investment returns through making venture capital investments in smaller companies United Kingdom 5
ATEL Capital Group United States 5
Axiom Venture Partners LP United States 5
BDC Venture Capital Group Canada 5
Biogen Idec New Ventures United States 5
Blue Chip Venture Co United States 5
China Development Industrial Bank China 5
Cinven Ltd British private equity firm focused on European acquisitions and buyouts. United Kingdom 5
Clarion Capital Partners LLC United States 5
Deerfield Capital Management LLC 5
Elm Street Ventures United States 5
Fidelity Investments Ltd United States 5

Pages

Selected funding rounds

Date Company Profile Round
Oct 2010 Auspex Pharmaceuticals Series C
Oct 2010 Essentialis Inc Developing a novel therapy for the treatment of dyslipidemia. Series B
Oct 2010 Essentialis Inc Developing a novel therapy for the treatment of dyslipidemia. Series B
23 Sep 2010 CytomX Therapeutics Developer of proteolytically-activated antibodies Series B
9 Sep 2010 IPierian Inc A biopharmaceutical company using patient-derived induced pluripotent stem cells for drug discovery Series B
Sep 2010 Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. Series D
Sep 2010 Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. Series D
Sep 2010 Tobira Therapeutics Inc Dedicated to the clinical development of antiviral products Series B
Sep 2010 Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. Series D
Sep 2010 Celator Pharmaceuticals Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers. Series D
Sep 2010 Tobira Therapeutics Inc Dedicated to the clinical development of antiviral products Series B
Sep 2010 Zyngenia Inc Series A
Sep 2010 Carex Health Brands Inc N/A
Sep 2010 Tobira Therapeutics Inc Dedicated to the clinical development of antiviral products Series B
Sep 2010 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
Sep 2010 Tobira Therapeutics Inc Dedicated to the clinical development of antiviral products Series B
Sep 2010 Tobira Therapeutics Inc Dedicated to the clinical development of antiviral products Series B
Sep 2010 IPierian Inc A biopharmaceutical company using patient-derived induced pluripotent stem cells for drug discovery Series B
Sep 2010 Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. Series D
Sep 2010 Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. Series D

Pages

Selected companies

Company type: 
Personalized medicine company specializing in pharmacogenetics
Company type: 
Switzerland-based drug company focused on CNS disorders
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products